news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

Meijing AI News,Dongwu Securities released a research report on August 13, giving Renfu Pharmaceutical (600079.SH, latest price: 20.1 yuan) a buy rating. The main reasons for the rating include: 1) Anesthetics have a long life cycle, high barriers, and the market continues to expand; 2) Yichang Renfu: Laying the foundation for the company, the leading anesthetic has high growth; 3) The innovative pipeline is expected to be realized, and other subsidiaries are developing steadily. Risk warning: Risk of price reduction in centralized procurement; risk of policy fluctuations; product research and development and business expansion are not as expected; risk of operating and management of controlling shareholders, etc.

AI comment: Renmin Pharmaceutical has received attention from 5 brokerage research reports in the past month, 4 of which were bought, with an average target price of 24.14 yuan, which is 4.04 yuan higher than the latest price of 20.1 yuan, and the average target price has increased by 20.1%.

Every headline (nbdtoutiao)——

(Reporter Cai Ding)

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. You will be responsible for your own risks if you act accordingly.

Daily Economic News